Research Triangle Park, NC, July 11, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical regenerative medicines company, today announced the appointment of industry veteran, Ashwin...
APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented evidence that agonism of the apelinergic system (APJ/apelin axis) triggers the repair of damaged pulmonary vascular endothelial cells. Through this novel mechanism of action, APIE Tx’s lead experimental drug candidate, APT-101 may have therapeutic benefit in the treatment of fibrotic lung diseases caused by the breakdown of the vascular endothelial niche, an endothelial cell barrier that protects the alveoli and promotes oxygen exchange.